EXCELLence
Co-financed by:
Project Definition | EXCELLence – Innovative Extracellular Nanotechnologies for Human Health
Project code | CENTRO2030-FEDER-01680300
Execution Region |Centre
Target Entity| Exogenus Therapeutics, S.A.
Starting date | 1st April 2025
Ending date | 31st March 2027
Total eligible costs |100.000,00€
European Union Financial support | 50.000,00€
Description
Exogenus Therapeutics recognises that sustained innovation, competitiveness, and long-term growth are closely linked to the company’s ability to develop and expand its technological and scientific capabilities.
In this context, the operation aims to support the submission of a portfolio of applications to European funding programmes, with the objectives of (i) continuing the development of the company’s most promising technology, Exo-101, currently at an advanced pre-clinical stage, enabling its progression into clinical development as a therapy for osteoarthritis, (ii) advancing the same technology towards additional therapeutic targets for which there is already evidence of significant potential, and (iii) broadening the company’s technological platform to additional therapeutic and non-therapeutic human health applications, with a particular focus on the use of raw materials discarded by other industries, following circular economy and industrial symbiosis principles.
This multi-project approach, ranging from early-stage concepts to advanced pre-clinical products, will enable Exogenus Therapeutics to continue progressing through the lengthy and resource-intensive pathway towards clinical application, while maintaining a strong commitment to innovation and simultaneously investing in new and more accessible market opportunities. The successful implementation of the applications planned over the next 24 months is expected to contribute not only to the development of new products, but also to the company’s medium-term sustainability and to its role in driving innovation in Portugal and internationally.